Browse

Inhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its cell therapy partner and Argenx got a revenue boost.

BioNTech is one of the most recent companies to announce cuts, but the pace of job losses is slowing.

The future of medicine is here. See how specialized logistics are saving lives with next-gen cell and gene therapies.